Coloma Jason V's Form 4 filing
Maze Therapeutics, Inc.MAZE · filed May 18, 2026
- Accession no.
- 0001676170-26-000004
- Filed
- May 18, 2026
- Trade date
- May 15, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $50.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Coloma Jason VCIK 0001676170 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | Common Stock | SSaleDisposed | −1,822 | $26.00 | −$47,372 | 381,073 | Indirect | |
| May 15, 2026 | Common Stock | SSaleDisposed | −116 | $26.00 | −$3,016 | 31,001 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
The securities reported on this Form 4 as attributable to the Family Trust and the Irrevocable Trust were incorrectly reported on the reporting person's Form 3 as directly held by the reporting person. This Form 4 corrects his Form 3 and restates the attribution of his holdings. All prior Section 16 reports filed on behalf of the reporting person should be understood to incorporate this correction.